FDA rejects schizophrenia drug from Teva
The US health authority has given its thumbs-down for a schizophrenia drug candidate developed by Teva in a collaboration with French biotech firm Medincell.
by albert rønning-andersson, translated by daniel pedersen
A potentially new treatment for schizophrenia has been sent back to the development phase, the pharmaceutical firm behind the drug, Teva, has announced in a press release on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk sues Teva over generic drug development
For subscribers
.jpg&w=384&q=75)
